Antithrombin III–heparin complex (ATIII–heparin complex (AT–heparin complex))

The Antithrombin III–heparin complex is formed when heparin binds to antithrombin III, inducing a specific conformational change that dramatically increases antithrombin’s ability to inhibit serine proteases in the coagulation cascade, such as thrombin and factor Xa[1][2][3][4]. Heparin specifically binds to a pentasaccharide sequence, which is present in only certain chains, triggering antithrombin III to become an efficient anticoagulant. This complex is the molecular target of heparin-based drugs and is central to the clinical management of thrombotic disorders, acting by limiting blood clot formation and propagation. Elevated activity of this complex is the chief basis for pharmacological anticoagulation with heparin and related agents[2][3][4]. Therapeutic manipulation relies heavily on the structural specificity and potency of this interaction, but carries a substantial risk for bleeding and requires careful clinical monitoring.

Other names

Antithrombin–heparin complexATIII–heparin complexAT–heparin complex

Potentiation of antithrombin III–mediated inhibition of clotting factors (thrombin and factor Xa)\nAllosteric activation by heparin binding, which induces conformational change in antithrombin III and enhances its inhibitory function